For example, KRAS drives the expression of COX-2, resulting in the production of the immune-suppressive prostaglandin E2, and the inhibition of COX-2 or prostaglandin E2 has been shown to increase sensitivity to anti-PD-1 when combined with KRAS inhibitors.307,308 Different therapeutic strategies exploiting the impact of KRAS inhibition on tumor immunity have been recently reviewed.309. The gene discussed is KRAS; the disease is neoplasm.